Candida auris: the new fungal threat
- PMID: 37701386
- PMCID: PMC10495051
- DOI: 10.53854/liim-3103-6
Candida auris: the new fungal threat
Abstract
Candida auris is an emergent fungal pathogen of particular concern. Since its first identification in Japan in 2009, it rapidly spread all over the world, including Italy. The main concern related to the diffusion of this fungus is its antifungal resistance. It is speculated that about 90% of isolates are resistant to fluconazole, 30% to amphotericin B and 5% to echinocandins; furthermore, some cases of pan-antifungal resistance have been described. Critically ill patients are particularly at risk of being colonized by this yeast and person-to-person transmission may generate hospital outbreaks. In fact, C. auris can survive on inanimate surfaces for a long time and commonly used disinfectants are not effective. Additionally, devices such as central venous catheters (CVCs) or urinary catheters are particularly at risk of being colonized, representing a possible source for the development of bloodstream infections caused by C. auris, which carries a high mortality rate. Given its capability to spread in the hospital setting and the limited therapeutic options it is of outmost importance to promptly identify C. auris. However, commonly used biochemical tests frequently misidentify C. auris as other Candida species; currently the best identification techniques are MALDI-TOF and molecular methods, such as PCR of the ITS and D1/D2 regions of the 28s ribosomal DNA. Whole genome sequencing remains the gold standard for the phylogenetic investigation of outbreaks. The majority of cases of colonization by C. albicans will not cause bloodstream infections and contact precautions and surveillance of contacts will be sufficient. When invasive fungal infections occur, echinocandins still represent the first therapeutic choice. A combination therapy or the use of novel antifungals (such as ibrexafungerp or fosmanogepix) would be required for echinocandin resistant strains. In conclusion, C. auris represents a growing threat because of its antifungal resistance characteristics, its difficult identification and its easy spread from person to person. The aim of this mini-review is to summarize the main aspects concerning this pathogen.
Keywords: Candida auris; antifungal resistance; epidemiology; novel therapies.
Conflict of interest statement
Conflict of interest The authors declare no conflict of interest.
Similar articles
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases.Intern Med J. 2019 Oct;49(10):1229-1243. doi: 10.1111/imj.14612. Intern Med J. 2019. PMID: 31424595 Review.
-
Candida auris: A pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains.J Infect Chemother. 2019 Oct;25(10):743-749. doi: 10.1016/j.jiac.2019.05.034. Epub 2019 Jun 28. J Infect Chemother. 2019. PMID: 31257156 Review.
-
Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.Clin Infect Dis. 2017 Jan 15;64(2):134-140. doi: 10.1093/cid/ciw691. Epub 2016 Oct 20. Clin Infect Dis. 2017. PMID: 27988485 Free PMC article.
-
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.Antimicrob Agents Chemother. 2022 Jul 19;66(7):e0005322. doi: 10.1128/aac.00053-22. Epub 2022 Jun 30. Antimicrob Agents Chemother. 2022. PMID: 35770999 Free PMC article.
Cited by
-
Protease production by Serratia liquefaciens NRC1 using fish gut waste as a sustainable approach to antimicrobial peptide generation and combating Candida auris acquired resistance.Microb Cell Fact. 2025 Jul 2;24(1):155. doi: 10.1186/s12934-025-02767-0. Microb Cell Fact. 2025. PMID: 40604960 Free PMC article.
-
Enhancing fluconazole reactivation against Candida auris: efficacy of Cinnamomum zeylanicum essential oil versus cinnamaldehyde.Microbiol Spectr. 2024 Apr 2;12(4):e0017624. doi: 10.1128/spectrum.00176-24. Epub 2024 Mar 14. Microbiol Spectr. 2024. PMID: 38483141 Free PMC article. No abstract available.
-
Current global status of Candida auris an emerging multidrug-resistant fungal pathogen: bibliometric analysis and network visualization.Braz J Microbiol. 2024 Mar;55(1):391-402. doi: 10.1007/s42770-023-01239-0. Epub 2024 Jan 23. Braz J Microbiol. 2024. PMID: 38261261 Free PMC article.
-
Re-estimation of the burden of serious fungal diseases in Uganda.Ther Adv Infect Dis. 2024 Feb 6;11:20499361241228345. doi: 10.1177/20499361241228345. eCollection 2024 Jan-Dec. Ther Adv Infect Dis. 2024. PMID: 38328511 Free PMC article.
-
Variable sensitivity of clinical Candida auris strains to Biocides: implications for infection control in Healthcare Settings.BMC Microbiol. 2024 Nov 4;24(1):447. doi: 10.1186/s12866-024-03605-w. BMC Microbiol. 2024. PMID: 39497071 Free PMC article.
References
-
- Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009 Jan;53(1):41–44. Erratum in: Microbiol Immunol2018; 62(3)205. - PubMed
Publication types
LinkOut - more resources
Full Text Sources